Internet of Medical Things Market by Device Type (Implantable Devices, Stationary Devices, Wearable Devices), Component (Connectivity Modules, Sensors, Services), Application, Connectivity Technology, End Use, Deployment Mode - Global Forecast 2025-2032
Description
The Internet of Medical Things Market was valued at USD 1.05 billion in 2024 and is projected to grow to USD 1.35 billion in 2025, with a CAGR of 28.54%, reaching USD 7.85 billion by 2032.
Framing the Internet of Medical Things revolution with foundational context, strategic imperatives, and immediate priorities for healthcare decision-makers
The Internet of Medical Things is redefining how care is delivered, monitored, and optimized by connecting clinical devices, consumer wearables, and care delivery systems into convergent ecosystems. This shifting topology is driven by increasingly sophisticated sensors, ubiquitous connectivity, and software platforms that translate device telemetry into clinical actions. As stakeholders across providers, payers, and vendors wrestle with interoperability, cybersecurity, and regulatory compliance, the immediate imperative is to articulate clear strategic priorities that align technology investments with care outcomes and operational efficiency.
Transitioning from isolated pilots to enterprise-scale deployments requires a pragmatic appreciation of infrastructure readiness, data governance, and cross-functional collaboration. Organizations that align clinical workflows with device-generated insights can compress decision cycles and improve patient-centric metrics, while those that treat IoT as an adjunct technology risk creating costly siloes. Consequently, leaders must prioritize architectures, governance models, and change management processes that enable the IoMT to function as an integrated component of care delivery rather than a collection of discrete point solutions.
Identifying the most disruptive technological and operational shifts reshaping medical device connectivity, patient care, and clinical workflows
Rapid technological advances and evolving care models are producing transformative shifts across the medical device connectivity landscape. Edge compute capabilities and federated analytics are moving intelligence closer to devices, enabling real-time clinical interventions and reducing latency for time-sensitive applications. Concurrently, advances in miniaturized sensors and low-power communications are broadening the scope of feasible monitoring scenarios, making long-term ambulatory sensing and minimally invasive implantables more viable than ever.
Operationally, care delivery models are decentralizing as remote patient monitoring and home-based care mature from pilot stages to accepted standards of care. This decentralization is reshaping procurement and clinical pathways, increasing the importance of standardized interfaces and vendor-neutral platforms. Meanwhile, regulatory agencies are clarifying expectations around software-as-a-medical-device and cybersecurity, which is prompting an elevated focus on secure development lifecycles and post-market surveillance. Together, these trends are forcing ecosystem participants to rethink product roadmaps, partnership strategies, and clinical validation approaches in order to capture the full promise of connected health.
Assessing the cumulative economic, supply chain, and compliance consequences of United States tariff measures on medical device connectivity in 2025
Tariff policies enacted or adjusted in 2025 have the potential to create compounding effects across procurement, supply chains, and regulatory compliance for connected medical devices. Higher import duties on hardware components and communication modules can increase landed costs, prompting manufacturers to reassess supplier footprints and component sourcing strategies. Over time, these cost pressures may accelerate regional manufacturing investments or encourage local sourcing partnerships to reduce exposure to cross-border tariff volatility.
In addition to direct cost implications, tariff-induced supplier changes can heighten supply chain complexity and risk. When manufacturers substitute components or change suppliers to mitigate tariff impact, they must navigate additional testing, certification, and clinical validation steps, which extend time-to-market and increase development costs. Regulatory compliance pathways may be affected if component provenance alters device performance characteristics, necessitating supplemental documentation and post-market evidence. As a result, organizations should anticipate a period of elevated procurement diligence and contingency planning, with near-term emphasis on contractual safeguards, multi-sourcing strategies, and inventory buffering to maintain continuity of clinical deployments.
Translating segment-level dynamics into strategic insight across device types, components, applications, connectivity technologies, end uses, and deployment modes
A nuanced view of segmentation reveals distinct strategic imperatives across device architectures, component ecosystems, clinical use cases, connectivity modalities, care settings, and deployment approaches. Implantable devices, stationary platforms, and wearable devices each impose different requirements for power management, form factor, and long-term data fidelity, which in turn influence choices around sensors, connectivity modules, embedded software, and downstream services. For example, implantables demand ultra-low-power sensors and highly reliable communication links, while stationary devices can leverage richer compute resources and more expansive software feature sets.
Component-level distinctions between connectivity modules, sensors, services, and software determine integration complexity and partner selection for systems integrators and device OEMs. Application areas such as asset tracking, chronic disease management, drug delivery, remote patient monitoring, and surgical telemetry drive unique validation protocols, latency tolerances, and data governance models. Similarly, connectivity technology decisions-ranging from Bluetooth Low Energy and Wi-Fi to cellular IoT, LPWAN, and Zigbee-must be made holistically, balancing range, throughput, power consumption, and security requirements for each clinical scenario. End-use environments including clinics, diagnostics centers, home healthcare, and hospitals present varying IT architectures, clinician workflows, and procurement pathways that directly affect solution design and commercialization strategy. Finally, choosing between cloud and on premises deployment modes influences integration cadence, data residency, and maintenance models, and organizations must reconcile these trade-offs to deliver reliable, compliant, and clinically valuable solutions.
Comparative regional dynamics and strategic opportunities across the Americas, Europe Middle East & Africa, and Asia-Pacific healthcare technology ecosystems
Regional dynamics will continue to shape strategic priorities for device makers, platform providers, and healthcare systems. In the Americas, mature provider networks and strong investment activity favor pilots transitioning to wider deployments, with an emphasis on interoperability, reimbursement alignment, and cybersecurity hardening. As a result, commercial strategies that prioritize clinical validation and payer engagement tend to perform well, and partnerships with health systems accelerate adoption of complex remote monitoring and chronic care programs.
In Europe, Middle East & Africa, regulatory sophistication and diverse market structures require adaptable go-to-market strategies that reconcile stringent data protection standards with variable infrastructure readiness across countries. Vendors that can provide configurable deployment models and robust compliance documentation gain traction in institutional settings. Across Asia-Pacific, rapid digitalization and substantial manufacturing capacity create both competitive manufacturing advantages and large addressable patient populations; this region is characterized by fast-paced adoption of consumer-grade monitoring devices integrated into large-scale public health initiatives. Across all regions, cross-border collaboration and localization strategies are essential to navigate differing procurement practices, regulatory regimes, and clinician expectations.
Competitive landscape intelligence highlighting strategic positioning, partnerships, innovation pathways, and risk exposure among leading Internet of Medical Things participants
Competitive dynamics in the IoMT ecosystem are shaped by a blend of product innovation, platform depth, partnership orchestration, and regulatory agility. Leaders differentiate through end-to-end offerings that pair certified hardware with clinical-grade software and managed services, enabling healthcare organizations to adopt connected solutions with fewer integration hurdles. Strategic partnerships between device manufacturers, connectivity providers, and systems integrators accelerate time-to-deployment by combining domain expertise with operational scale.
Innovation pathways increasingly emphasize modular architectures and open standards to reduce lock-in and facilitate third-party application development. At the same time, companies that invest in rigorous clinical validation and post-market evidence generation build stronger trust among providers and regulators. Mergers and acquisitions are commonly pursued to fill capability gaps-whether in analytics, cybersecurity, or regulatory affairs-while strategic alliances enable access to distribution channels and payer relationships. For market participants, the imperative is to balance horizontal platform playbooks with verticalized clinical solutions that demonstrate clear care pathway improvements and measurable operational benefits.
Practical and prioritized strategic recommendations for industry leaders to accelerate adoption, manage risk, and capture value from Internet of Medical Things initiatives
Industry leaders should prioritize a tight, executable set of actions to translate strategic intent into measurable outcomes. First, align clinical and commercial objectives by defining high-impact use cases and validating them with pilot cohorts that reflect target patient populations and care settings. Next, establish robust interoperability and security standards within procurement specifications to avoid costly rip-and-replace cycles and to ensure regulatory readiness. This includes defining secure development lifecycles, threat modeling, and incident response playbooks that are integrated with provider security operations.
Simultaneously, adopt flexible sourcing models that combine multi-sourcing, regional manufacturing options, and built-in component substitution strategies to reduce supply chain exposure to tariff and logistical disruptions. Invest in modular software architectures and API-first integrations to accelerate partner onboarding and to support differentiated analytics and clinical decision support. Finally, build cross-functional governance that includes clinical, IT, legal, and procurement stakeholders to oversee deployment, outcomes tracking, and lifecycle management, thereby ensuring that connected devices deliver sustained clinical and economic value.
Robust research approach detailing data sources, analytical frameworks, validation techniques, and limitations that underpin the Internet of Medical Things analysis
The research approach combined a multi-method design that integrated primary interviews, technical validation, and secondary literature review to ensure robustness and relevance. Primary inputs included structured interviews with clinical leaders, procurement officers, device engineers, and cybersecurity specialists to capture operational pain points and adoption drivers. Technical validation was performed through device interoperability testing scenarios and review of standards compliance artifacts to assess real-world integration constraints and performance characteristics.
Secondary analysis drew on regulatory guidance, standards bodies, and publicly available technical documentation to map evolving compliance expectations and technology roadmaps. The analytical framework applied scenario-based stress testing to evaluate supply chain and tariff-related contingencies, and qualitative synthesis techniques were used to translate stakeholder needs into strategic imperatives. Limitations include variability in organizational readiness across regions and rapidly evolving regulatory landscapes; where appropriate, findings have been qualified to reflect these uncertainties and to recommend further organization-specific validation prior to large-scale investments.
Synthesis of strategic implications, emerging opportunities, and critical next steps for stakeholders across the Internet of Medical Things ecosystem
Connected medical devices represent a pivotal inflection point for care delivery, offering opportunities to improve patient outcomes, streamline workflows, and enable new care models. Realizing these benefits, however, requires deliberate alignment of technology choices with clinical objectives, robust cybersecurity and regulatory postures, and supply chain resilience to accommodate macroeconomic disruptions. Sustainable success will be achieved by organizations that invest in interoperable platforms, clinically validated solutions, and governance structures that bridge clinical, technical, and commercial teams.
Looking ahead, the most successful stakeholders will be those that combine pragmatic piloting with scalable architectures, prioritize patient safety and data integrity, and cultivate flexible partnerships to adapt to tariff and supply chain dynamics. By focusing on measurable clinical impact, modular technology design, and cross-functional execution, healthcare organizations and vendors can turn the promise of connected care into operational reality and create differentiated value across the care continuum.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Device Type
Implantable Devices
Stationary Devices
Wearable Devices
Component
Connectivity Modules
Sensors
Services
Software
Application
Asset Tracking
Chronic Disease Management
Drug Delivery
Remote Patient Monitoring
Surgical Telemetry
Connectivity Technology
Bluetooth Low Energy
Cellular IoT
LPWAN
Wi-Fi
Zigbee
End Use
Clinics
Diagnostics Centers
Home Healthcare
Hospitals
Deployment Mode
Cloud
On Premises
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
Koninklijke Philips N.V.
GE HealthCare
Siemens Healthineers AG
Medtronic PLC
Abbott Laboratories
Cisco Systems, Inc.
Intel Corporation
Honeywell International Inc.
Qualcomm Incorporated
International Business Machines Corporation
Please Note: PDF & Excel + Online Access - 1 Year
Framing the Internet of Medical Things revolution with foundational context, strategic imperatives, and immediate priorities for healthcare decision-makers
The Internet of Medical Things is redefining how care is delivered, monitored, and optimized by connecting clinical devices, consumer wearables, and care delivery systems into convergent ecosystems. This shifting topology is driven by increasingly sophisticated sensors, ubiquitous connectivity, and software platforms that translate device telemetry into clinical actions. As stakeholders across providers, payers, and vendors wrestle with interoperability, cybersecurity, and regulatory compliance, the immediate imperative is to articulate clear strategic priorities that align technology investments with care outcomes and operational efficiency.
Transitioning from isolated pilots to enterprise-scale deployments requires a pragmatic appreciation of infrastructure readiness, data governance, and cross-functional collaboration. Organizations that align clinical workflows with device-generated insights can compress decision cycles and improve patient-centric metrics, while those that treat IoT as an adjunct technology risk creating costly siloes. Consequently, leaders must prioritize architectures, governance models, and change management processes that enable the IoMT to function as an integrated component of care delivery rather than a collection of discrete point solutions.
Identifying the most disruptive technological and operational shifts reshaping medical device connectivity, patient care, and clinical workflows
Rapid technological advances and evolving care models are producing transformative shifts across the medical device connectivity landscape. Edge compute capabilities and federated analytics are moving intelligence closer to devices, enabling real-time clinical interventions and reducing latency for time-sensitive applications. Concurrently, advances in miniaturized sensors and low-power communications are broadening the scope of feasible monitoring scenarios, making long-term ambulatory sensing and minimally invasive implantables more viable than ever.
Operationally, care delivery models are decentralizing as remote patient monitoring and home-based care mature from pilot stages to accepted standards of care. This decentralization is reshaping procurement and clinical pathways, increasing the importance of standardized interfaces and vendor-neutral platforms. Meanwhile, regulatory agencies are clarifying expectations around software-as-a-medical-device and cybersecurity, which is prompting an elevated focus on secure development lifecycles and post-market surveillance. Together, these trends are forcing ecosystem participants to rethink product roadmaps, partnership strategies, and clinical validation approaches in order to capture the full promise of connected health.
Assessing the cumulative economic, supply chain, and compliance consequences of United States tariff measures on medical device connectivity in 2025
Tariff policies enacted or adjusted in 2025 have the potential to create compounding effects across procurement, supply chains, and regulatory compliance for connected medical devices. Higher import duties on hardware components and communication modules can increase landed costs, prompting manufacturers to reassess supplier footprints and component sourcing strategies. Over time, these cost pressures may accelerate regional manufacturing investments or encourage local sourcing partnerships to reduce exposure to cross-border tariff volatility.
In addition to direct cost implications, tariff-induced supplier changes can heighten supply chain complexity and risk. When manufacturers substitute components or change suppliers to mitigate tariff impact, they must navigate additional testing, certification, and clinical validation steps, which extend time-to-market and increase development costs. Regulatory compliance pathways may be affected if component provenance alters device performance characteristics, necessitating supplemental documentation and post-market evidence. As a result, organizations should anticipate a period of elevated procurement diligence and contingency planning, with near-term emphasis on contractual safeguards, multi-sourcing strategies, and inventory buffering to maintain continuity of clinical deployments.
Translating segment-level dynamics into strategic insight across device types, components, applications, connectivity technologies, end uses, and deployment modes
A nuanced view of segmentation reveals distinct strategic imperatives across device architectures, component ecosystems, clinical use cases, connectivity modalities, care settings, and deployment approaches. Implantable devices, stationary platforms, and wearable devices each impose different requirements for power management, form factor, and long-term data fidelity, which in turn influence choices around sensors, connectivity modules, embedded software, and downstream services. For example, implantables demand ultra-low-power sensors and highly reliable communication links, while stationary devices can leverage richer compute resources and more expansive software feature sets.
Component-level distinctions between connectivity modules, sensors, services, and software determine integration complexity and partner selection for systems integrators and device OEMs. Application areas such as asset tracking, chronic disease management, drug delivery, remote patient monitoring, and surgical telemetry drive unique validation protocols, latency tolerances, and data governance models. Similarly, connectivity technology decisions-ranging from Bluetooth Low Energy and Wi-Fi to cellular IoT, LPWAN, and Zigbee-must be made holistically, balancing range, throughput, power consumption, and security requirements for each clinical scenario. End-use environments including clinics, diagnostics centers, home healthcare, and hospitals present varying IT architectures, clinician workflows, and procurement pathways that directly affect solution design and commercialization strategy. Finally, choosing between cloud and on premises deployment modes influences integration cadence, data residency, and maintenance models, and organizations must reconcile these trade-offs to deliver reliable, compliant, and clinically valuable solutions.
Comparative regional dynamics and strategic opportunities across the Americas, Europe Middle East & Africa, and Asia-Pacific healthcare technology ecosystems
Regional dynamics will continue to shape strategic priorities for device makers, platform providers, and healthcare systems. In the Americas, mature provider networks and strong investment activity favor pilots transitioning to wider deployments, with an emphasis on interoperability, reimbursement alignment, and cybersecurity hardening. As a result, commercial strategies that prioritize clinical validation and payer engagement tend to perform well, and partnerships with health systems accelerate adoption of complex remote monitoring and chronic care programs.
In Europe, Middle East & Africa, regulatory sophistication and diverse market structures require adaptable go-to-market strategies that reconcile stringent data protection standards with variable infrastructure readiness across countries. Vendors that can provide configurable deployment models and robust compliance documentation gain traction in institutional settings. Across Asia-Pacific, rapid digitalization and substantial manufacturing capacity create both competitive manufacturing advantages and large addressable patient populations; this region is characterized by fast-paced adoption of consumer-grade monitoring devices integrated into large-scale public health initiatives. Across all regions, cross-border collaboration and localization strategies are essential to navigate differing procurement practices, regulatory regimes, and clinician expectations.
Competitive landscape intelligence highlighting strategic positioning, partnerships, innovation pathways, and risk exposure among leading Internet of Medical Things participants
Competitive dynamics in the IoMT ecosystem are shaped by a blend of product innovation, platform depth, partnership orchestration, and regulatory agility. Leaders differentiate through end-to-end offerings that pair certified hardware with clinical-grade software and managed services, enabling healthcare organizations to adopt connected solutions with fewer integration hurdles. Strategic partnerships between device manufacturers, connectivity providers, and systems integrators accelerate time-to-deployment by combining domain expertise with operational scale.
Innovation pathways increasingly emphasize modular architectures and open standards to reduce lock-in and facilitate third-party application development. At the same time, companies that invest in rigorous clinical validation and post-market evidence generation build stronger trust among providers and regulators. Mergers and acquisitions are commonly pursued to fill capability gaps-whether in analytics, cybersecurity, or regulatory affairs-while strategic alliances enable access to distribution channels and payer relationships. For market participants, the imperative is to balance horizontal platform playbooks with verticalized clinical solutions that demonstrate clear care pathway improvements and measurable operational benefits.
Practical and prioritized strategic recommendations for industry leaders to accelerate adoption, manage risk, and capture value from Internet of Medical Things initiatives
Industry leaders should prioritize a tight, executable set of actions to translate strategic intent into measurable outcomes. First, align clinical and commercial objectives by defining high-impact use cases and validating them with pilot cohorts that reflect target patient populations and care settings. Next, establish robust interoperability and security standards within procurement specifications to avoid costly rip-and-replace cycles and to ensure regulatory readiness. This includes defining secure development lifecycles, threat modeling, and incident response playbooks that are integrated with provider security operations.
Simultaneously, adopt flexible sourcing models that combine multi-sourcing, regional manufacturing options, and built-in component substitution strategies to reduce supply chain exposure to tariff and logistical disruptions. Invest in modular software architectures and API-first integrations to accelerate partner onboarding and to support differentiated analytics and clinical decision support. Finally, build cross-functional governance that includes clinical, IT, legal, and procurement stakeholders to oversee deployment, outcomes tracking, and lifecycle management, thereby ensuring that connected devices deliver sustained clinical and economic value.
Robust research approach detailing data sources, analytical frameworks, validation techniques, and limitations that underpin the Internet of Medical Things analysis
The research approach combined a multi-method design that integrated primary interviews, technical validation, and secondary literature review to ensure robustness and relevance. Primary inputs included structured interviews with clinical leaders, procurement officers, device engineers, and cybersecurity specialists to capture operational pain points and adoption drivers. Technical validation was performed through device interoperability testing scenarios and review of standards compliance artifacts to assess real-world integration constraints and performance characteristics.
Secondary analysis drew on regulatory guidance, standards bodies, and publicly available technical documentation to map evolving compliance expectations and technology roadmaps. The analytical framework applied scenario-based stress testing to evaluate supply chain and tariff-related contingencies, and qualitative synthesis techniques were used to translate stakeholder needs into strategic imperatives. Limitations include variability in organizational readiness across regions and rapidly evolving regulatory landscapes; where appropriate, findings have been qualified to reflect these uncertainties and to recommend further organization-specific validation prior to large-scale investments.
Synthesis of strategic implications, emerging opportunities, and critical next steps for stakeholders across the Internet of Medical Things ecosystem
Connected medical devices represent a pivotal inflection point for care delivery, offering opportunities to improve patient outcomes, streamline workflows, and enable new care models. Realizing these benefits, however, requires deliberate alignment of technology choices with clinical objectives, robust cybersecurity and regulatory postures, and supply chain resilience to accommodate macroeconomic disruptions. Sustainable success will be achieved by organizations that invest in interoperable platforms, clinically validated solutions, and governance structures that bridge clinical, technical, and commercial teams.
Looking ahead, the most successful stakeholders will be those that combine pragmatic piloting with scalable architectures, prioritize patient safety and data integrity, and cultivate flexible partnerships to adapt to tariff and supply chain dynamics. By focusing on measurable clinical impact, modular technology design, and cross-functional execution, healthcare organizations and vendors can turn the promise of connected care into operational reality and create differentiated value across the care continuum.
Market Segmentation & Coverage
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
Device Type
Implantable Devices
Stationary Devices
Wearable Devices
Component
Connectivity Modules
Sensors
Services
Software
Application
Asset Tracking
Chronic Disease Management
Drug Delivery
Remote Patient Monitoring
Surgical Telemetry
Connectivity Technology
Bluetooth Low Energy
Cellular IoT
LPWAN
Wi-Fi
Zigbee
End Use
Clinics
Diagnostics Centers
Home Healthcare
Hospitals
Deployment Mode
Cloud
On Premises
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
Americas
North America
United States
Canada
Mexico
Latin America
Brazil
Argentina
Chile
Colombia
Peru
Europe, Middle East & Africa
Europe
United Kingdom
Germany
France
Russia
Italy
Spain
Netherlands
Sweden
Poland
Switzerland
Middle East
United Arab Emirates
Saudi Arabia
Qatar
Turkey
Israel
Africa
South Africa
Nigeria
Egypt
Kenya
Asia-Pacific
China
India
Japan
Australia
South Korea
Indonesia
Thailand
Malaysia
Singapore
Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
Koninklijke Philips N.V.
GE HealthCare
Siemens Healthineers AG
Medtronic PLC
Abbott Laboratories
Cisco Systems, Inc.
Intel Corporation
Honeywell International Inc.
Qualcomm Incorporated
International Business Machines Corporation
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
190 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of AI-powered remote patient monitoring platforms for chronic disease management
- 5.2. Adoption of blockchain-based data security frameworks in connected medical device networks
- 5.3. Deployment of 5G-enabled wearable health trackers for real-time biometric data transmission
- 5.4. Advancement of edge computing solutions for low-latency processing in critical care devices
- 5.5. Regulatory approval challenges influencing interoperability standards across diverse IoMT ecosystems
- 5.6. Integration of telemedicine services with IoT-enabled diagnostic imaging and lab equipment platforms
- 5.7. Utilization of predictive analytics in hospital asset tracking systems to optimize resource allocation
- 5.8. Emergence of cybersecurity insurance models tailored for IoMT device manufacturers and service providers
- 5.9. Growth of smart medication adherence apps using connected pill dispensers and patient engagement tools
- 5.10. Expansion of cloud-based IoMT analytics platforms facilitating cross-institutional health data collaboration
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Internet of Medical Things Market, by Device Type
- 8.1. Implantable Devices
- 8.2. Stationary Devices
- 8.3. Wearable Devices
- 9. Internet of Medical Things Market, by Component
- 9.1. Connectivity Modules
- 9.2. Sensors
- 9.3. Services
- 9.4. Software
- 10. Internet of Medical Things Market, by Application
- 10.1. Asset Tracking
- 10.2. Chronic Disease Management
- 10.3. Drug Delivery
- 10.4. Remote Patient Monitoring
- 10.5. Surgical Telemetry
- 11. Internet of Medical Things Market, by Connectivity Technology
- 11.1. Bluetooth Low Energy
- 11.2. Cellular IoT
- 11.3. LPWAN
- 11.4. Wi-Fi
- 11.5. Zigbee
- 12. Internet of Medical Things Market, by End Use
- 12.1. Clinics
- 12.2. Diagnostics Centers
- 12.3. Home Healthcare
- 12.4. Hospitals
- 13. Internet of Medical Things Market, by Deployment Mode
- 13.1. Cloud
- 13.2. On Premises
- 14. Internet of Medical Things Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Internet of Medical Things Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Internet of Medical Things Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Koninklijke Philips N.V.
- 17.3.2. GE HealthCare
- 17.3.3. Siemens Healthineers AG
- 17.3.4. Medtronic PLC
- 17.3.5. Abbott Laboratories
- 17.3.6. Cisco Systems, Inc.
- 17.3.7. Intel Corporation
- 17.3.8. Honeywell International Inc.
- 17.3.9. Qualcomm Incorporated
- 17.3.10. International Business Machines Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
